Related Experiment Video

Updated: May 30, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.0K

Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance

Wen Li1, Xiaoxian Shi1, Caiwei Tan2

  • 1Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.

Nature Chemical Biology
|January 27, 2025
PubMed

Insights

ARAF protein forms unique condensates with RAS, boosting RAS activity and promoting cancer growth. Targeting these ARAF-RAS condensates may overcome drug resistance in various cancers.

Area of Science:

  • Molecular biology
  • Cell signaling
  • Cancer research

Background:

  • RAF kinases, including ARAF, are key RAS pathway effectors.
  • While all RAFs bind RAS, ARAF uniquely amplifies RAS activity.
  • The mechanism behind ARAF's unique RAS regulation was previously unclear.

Purpose of the Study:

  • To elucidate the molecular basis of ARAF's role in RAS activation.
  • To investigate the formation and function of ARAF-RAS structures.
  • To explore the therapeutic implications of targeting ARAF-RAS interactions.

Main Methods:

  • Investigated ARAF self-assembly and condensate formation.
  • Analyzed the impact of ARAF N-terminal sequence on RAS activation.
  • Examined ARAF-RAS condensate roles in receptor tyrosine kinase (RTK) signaling.
  • Assessed the effects of ARAF manipulation in RAS-mutant tumors and hormone-sensitive cancers.

Main Results:

  • ARAF's disordered N-terminus drives self-assembly into ARAF-RAS condensates at the plasma membrane.
  • These condensates concentrate active RAS, inhibiting negative regulation by NF1 and enhancing RTK-triggered RAS activation.
  • Loss of the ARAF N-terminus sensitizes RAS-mutant tumors to pan-RAF inhibitors.
  • Increased ARAF condensates contribute to endocrine therapy resistance in hormone-sensitive cancers, while ARAF depletion reverses RTK-dependent resistance.

Conclusions:

  • ARAF-RAS protein condensates are distinct subcellular structures that sustain RAS activity and oncogenic signaling.
  • Targeting ARAF-RAS condensation presents a potential strategy for overcoming drug resistance in both wild-type and mutant RAS-driven cancers.

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

934
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.1K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Rab Proteins01:14

Rab Proteins

Rab proteins constitute the largest family of monomeric GTPases, of which 70 members are present in humans. Rab proteins and their effectors regulate consecutive stages of vesicle transport such as vesicle transport, docking, and fusion to the correct recipient membrane.
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K